Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Nay M. Htun"'
Publikováno v:
Cardiovascular Revascularization Medicine. 39:84-89
BACKGROUND High levels of inflammation pre- and post-percutaneous coronary intervention (PCI) are associated with worse outcomes. Recent trials have suggested a benefit from treating inflammation with colchicine in coronary artery disease. In this ra
Autor:
Antony Walton, Stephen J. Duffy, Ronald J.L. Dick, Shane Nanayakkara, P. Vriesendorp, Nay M. Htun, Dion Stub, Joshua Bowditch, J. Stehli, M. Dagan
Publikováno v:
Heart, Lung and Circulation. 30:1910-1917
To compare short- and long-term outcomes after transcatheter aortic valve implantation (TAVI) in the public and private hospital setting.Propensity-matched, retrospective analysis of a prospective registry.Patients with severe aortic stenosis who und
Autor:
Nay M Htun, Dianna J Magliano, Zhen-Yu Zhang, Jasmine Lyons, Thibault Petit, Esther Nkuipou-Kenfack, Adela Ramirez-Torres, Constantin von Zur Muhlen, David Maahs, Joost P Schanstra, Claudia Pontillo, Martin Pejchinovski, Janet K Snell-Bergeon, Christian Delles, Harald Mischak, Jan A Staessen, Jonathan E Shaw, Thomas Koeck, Karlheinz Peter
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0172036 (2017)
Identification of individuals who are at risk of suffering from acute coronary syndromes (ACS) may allow to introduce preventative measures. We aimed to identify ACS-related urinary peptides, that combined as a pattern can be used as prognostic bioma
Externí odkaz:
https://doaj.org/article/0834ec4f1c00488794762f716885111a
Publikováno v:
Heart, Lung and Circulation. 30:547-554
Background Recent studies have shown that transcatheter aortic valve implantation (TAVI) is non-inferior to surgical aortic valve replacement (SAVR) for treatment of low-risk patients with severe aortic stenosis (AS). However, the cost-effectiveness
Autor:
Jason Bloom, William J. van Gaal, C. Hiew, Heath Adams, Andy S.C. Yong, Ravinay Bhindi, William Wilson, Jamie Layland, Padeepa Perera, Nicholas Collins, Arthur Nasis, Allysha Yeap, Kaleab N Asrress, Philip Roberts-Thomson, Astin Lee, Robert Whitbourn, Laurie Howes, Rumes Sriamareswaran, Melanie Freeman, Stephen Quinn, Brian Yip, Sam Wu, Nay M. Htun, Manuja Premaratne, Dion Stub, David C. Tong, John Amerena
Publikováno v:
Circulation. 144:1584-1586
Autor:
Julia Stehli, Misha Dagan, Stephen J. Duffy, Stéphane Morisset, Pieter Vriesendorp, Shane Nanayakkara, Ji Quan Samuel Koh, Edward Quine, Nay M. Htun, Dion Stub, Ron Dick, Antony S. Walton
Publikováno v:
Heart, lungcirculation.
To evaluate the long-term incidence of structural valve deterioration (SVD) in patients who underwent transcatheter aortic valve implantation (TAVI).Between 2008 and 2018, 693 underwent TAVI at two centres. Four hundred and twenty-one (421) patients
Publikováno v:
Heart, Lung and Circulation. 29:1174-1179
Transcatheter aortic valve implantation (TAVI) has been shown to be a safe and effective alternative to surgical aortic valve replacement (SAVR) in high- and intermediate-risk patients with severe aortic stenosis. TAVI for patients at lower risk of p
Autor:
Stephen J. Duffy, Rohan V. Navani, E. Quine, Nay M. Htun, Antony Walton, Dion Stub, Shane Nanayakkara
Publikováno v:
The American journal of cardiology. 163
The platelet-to-lymphocyte ratio (PLR) is a novel inflammatory biomarker that has prognostic value in patients presenting with acute coronary syndrome. Transcatheter aortic valve implantation (TAVI) treats the inflammatory disease of aortic stenosis.
Publikováno v:
International Journal of Cardiology. 294:17-22
Background The recent PARTNER S3i trial compared transcatheter aortic valve implantation (TAVI) using the third-generation SAPIEN 3 device to surgical aortic valve replacement (SAVR) in intermediate-risk patients with severe symptomatic aortic stenos
Autor:
Steffen U. Eisenhardt, Philipp Diehl, Maria Fuller, Thomas Helbing, Frederik Nienaber, Natalie A. Mellett, Xiaowei Wang, Patrick M. Siegel, Peter J. Meikle, Jonathon Habersberger, James D. McFadyen, Christoph Bode, Nicole Bassler, Gerhard Puetz, Karlheinz Peter, Yung-Chih Chen, Marius Wessinger, David Braig, Johannes Stamm, Maria T.K. Zaldivia, Nay M. Htun
Publikováno v:
Thrombosis and Haemostasis. 119:1295-1310
Background Microvesicles (MVs) are small cell-derived vesicles, which are mainly released by activated cells. They are part of a communication network delivering biomolecules, for example, inflammatory molecules, via the blood circulation to remote c